Fundraising FoxArtax Biopharma
Cambridge, US · Founded 2013 · 3 known investors
Find your way into Artax Biopharma
Each arrow is one introduction. Sign up to fill in the first one.
399 people can intro you to Maria
Ask Felice Verduyn - Van Weegen to introduce you to Maria Nichol
You →Felice · together at Agomab Therapeutics →Maria
277 people can intro you to Damia
Ask Jamie Chen to introduce you to Damia Tormo
You →Jamie · together at BiOncotech Therapeutics →Damia
Sign up to find every way you can get introduced to Artax Biopharma
- Your email: who you already know at Artax Biopharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Artax Biopharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression. Its lead candidate AX-158 has shown Phase 2a data in psoriasis, with additional Phase 2 trials planned in atopic dermatitis and rheumatoid arthritis.
Founders & leadership
Artax Biopharma was founded in 2013 by Damia Tormo.
DT
Damia TormoDirector & FounderDamia Tormo studied biology and has spent her career developing biotechnology therapeutics. She previously worked at Columbus Venture Partners, where she identified opportunities in vaccines, cancer treatments, and other healthcare solutions.
JS
Joe SuarezExecutive
MN
Maria NicholChief Business OfficerMaria Nichol is an in-house patent attorney with experience in the biotech and pharma sectors, with expertise in invention protection, patent prosecution, freedom-to-operate analysis, and patentability assessment.
RW
Robert W. Armstrong, Ph.D.Executive
Board
AH
Andre HoekemaBoard director
AW
DT
Damia Tormo, Ph.D.Board director
CB
RP
JG
Javier GarciaBoard director
GS
Gino SantiniBoard director
Investors · 3
Sound Bioventureslisted by Sound BioventuresMalmö
How we know: Sound Bioventures's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
Advent Life SciencesreportedLondonvia Raj Parekh · board
How we know: board seat on SEC Form D · funding news · Not right? Tell us
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred
How we know: funding news · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$54.7M disclosed across 7 rounds · 2014–2024
▶$19MraisedMay 2026 · 30 investors · PharmaceuticalsRule 506(b)
▶$19MraisedMay 2026 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joe SuarezExecutive Officer
- Andre HoekemaDirector
- Maria NicholExecutive Officer
- Alan WaltsDirector
- Damia Tormo, Ph.D.Director
- Gino SantiniDirector
- Casper BreumDirector
- Raj ParekhDirector
- Robert W. Armstrong, Ph.D.Executive Officer, Director
- Offering amount
- $19M
- Amount sold
- $19M
- Proceeds to insiders
- $3.5M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.8MraisedMay 2022 · 28 investors · BiotechnologyRule 506(b)
▶$25.8MraisedMay 2022 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan E. WaltsDirector
- Raj ParekhDirector
- Joseph M. LobackiExecutive Officer, Director
- Casper BreumDirector
- Robert Armstrong, Ph.D.Director
- Gino SantiniDirector
- Damia Tormo, Ph.D.Director
- Offering amount
- $25.8M
- Amount sold
- $25.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedFeb 2021 · 19 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gino SantiniDirector
- Damia TormoDirector
- Joseph M. LobackiExecutive Officer, Director
- Robert Armstrong, Ph.D.Director
- Alan E. WaltsDirector
- Offering amount
- $3M
- Amount sold
- $2.2M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMay 2020 · 9 investors · BiotechnologyRule 506(b)
▶$2MraisedMay 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan E. WaltsDirector
- Joseph M. LobackiExecutive Officer, Director
- Javier GarciaDirector
- Robert Armstrong, Ph.D.Director
- Gino SantiniDirector
- Damia Tormo, Ph.D.Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Apr 2020
- Incorporated
- Corporation, Massachusetts
- Federal exemptions
- 06b
▶$750KraisedAug 2019 · 24 investors · BiotechnologyRule 506(b)
▶$750KraisedAug 2019 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Damia Tormo, Ph.D., MBMExecutive Officer, Director
- Robert Armstrong, Ph.D.Director
- Alan E. WaltsDirector
- Gino SantiniDirector
- Javier GarciaDirector
- Offering amount
- $3.5M
- Amount sold
- $750K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedOct 2015 · 29 investors · BiotechnologyRule 506(c)
▶$3MraisedOct 2015 · 29 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Raj ParekhDirector
- Gino SantiniDirector
- Damia TormoExecutive Officer, Director
- Henri TermeerDirector
- Peter B. FinnExecutive Officer
- Javier GarciaDirector
- Robert W. Armstrong, Ph.D.Director
- Offering amount
- $10M
- Amount sold
- $3M
- Minimum investment
- $5K
- Proceeds to insiders
- $250K
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06c
▶$2MraisedNov 2014 · 18 investors · BiotechnologyRule 506(c)
▶$2MraisedNov 2014 · 18 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jan de Vries, Ph.D.Director
- Peter B. FinnExecutive Officer
- Robert W. Armstrong, Ph.D.Director
- Gino SantiniDirector
- Damia TormoExecutive Officer, Director
- Javier GarciaDirector
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $5K
- Proceeds to insiders
- $349.8K
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Artax Biopharma went on to found or lead other companies.
Related companies · 6
ADARx PharmaceuticalsADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Aclaris TherapeuticsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
Addex TherapeuticsAddex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
AmylyxAmylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
Companies working in the same space as Artax Biopharma.
In the news
Frequently asked questions
- What does Artax Biopharma do?
- Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression. Its lead candidate AX-158 has shown Phase 2a data in psoriasis, with additional Phase 2 trials planned in atopic dermatitis and rheumatoid arthritis.
- Who founded Artax Biopharma?
- Artax Biopharma was founded by Damia Tormo in 2013.
- Who are Artax Biopharma's investors?
- Artax Biopharma's investors include Sound Bioventures, Advent Life Sciences, Columbus Venture Partners.
- How much funding has Artax Biopharma raised?
- Artax Biopharma has disclosed $54.7M raised across 7 rounds.
- Where is Artax Biopharma headquartered?
- Artax Biopharma is headquartered in Cambridge, US.